SCHEMBL39522

SCHEMBL39522

CN(C(=O)c1c(O)c2c(Cl)cccc2[nH]c1=O)c1ccccc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GRIN2D O15399 2/20 0.49
GRIN3B O60391 2/20 0.49
GRIN1 Q05586 2/20 0.49
GRIN2A Q12879 2/20 0.49
GRIN2B Q13224 2/20 0.49
GRIN2C Q14957 2/20 0.49
GRIN3A Q8TCU5 2/20 0.49
POLB P06746 1/20 0.48
SERPINE1 P05121 1/20 0.45
GPBAR1 Q8TDU6 1/20 0.42
MEN1 O00255 1/20 0.42
PGR P06401 1/20 0.42
KMT2A Q03164 1/20 0.42
PTGS2 P35354 1/20 0.41
P2RX7 Q99572 1/20 0.40
MAP3K5 Q99683 1/20 0.39
CHEK1 O14757 1/20 0.39
GNRHR P30968 1/20 0.38
PBRM1 Q86U86 1/20 0.38
DAO P14920 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6202118 0.88 MEN1 (0.43) POLBMEN1PGRKMT2APTGS2
SCHEMBL15200742 0.88 KMT2A (0.43) POLBMEN1PGRKMT2APTGS2
SCHEMBL18751640 0.85 TP53 (0.51) GRIN2DGRIN3BGRIN1GRIN2AGRIN2B
SCHEMBL7560668 0.85 POLB (0.45) GRIN2DGRIN3BGRIN1GRIN2AGRIN2B
SCHEMBL7818937 0.83 PTGS2 (0.44) GRIN2DGRIN3BGRIN1GRIN2AGRIN2B
SCHEMBL12009980 0.81 GRIN2D (0.43) GRIN2DGRIN3BGRIN1GRIN2AGRIN2B
SCHEMBL852747 0.81 KMT2A (0.55) POLBMEN1PGRKMT2A
SCHEMBL3466280 0.79 POLB (0.41) POLBGPBAR1MEN1PGRKMT2A
SCHEMBL7563981 0.78 GPBAR1 (0.40) POLBGPBAR1MEN1PGRKMT2A
SCHEMBL11983217 0.77 KDM4E (0.50) POLBMEN1KMT2APTGS2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2597954-A1 DEUTERATED N-ETHYL-N-PHENYL-1,2-DIHYDRO-4-HYDROXY-5-CHLORO-1-METHYL-2-OXOQUINOLINE-3-CARBOXAMIDE, SALTS AND USES THEREOF Teva Pharmaceutical Industries Ltd. (IL) 2013-06-05 EP claimed
EP-2590653-A1 5-CHLORO-4-HYDROXY-1-METHYL-2-OXO-N-PHENYL-1,2-DIHYDROQUINOLINE-3-CARBOXAMIDE, SALTS AND USES THEREOF Teva Pharmaceutical Industries Ltd. (IL) 2013-05-15 EP claimed
WO-2012006538-A1 DEUTERATED N-ETHYL-N-PHENYL-1,2-DIHYDRO-4-HYDROXY-5-CHLORO-1-METHYL-2-OXOQUINOLINE-3-CARBOXAMIDE, SALTS AND USES THEREOF TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) 2012-01-12 WO claimed
WO-2012006544-A1 5-CHLORO-4-HYDROXY-1-METHYL-2-OXO-N-PHENYL-1,2-DIHYDROQUINOLINE-3-CARBOXAMIDE, SALTS AND USES THEREOF TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) 2012-01-12 WO claimed
EP-2234485-A1 STABLE LAQUINIMOD PREPARATIONS Teva Pharmaceutical Industries Ltd. (IL) 2010-10-06 EP claimed
WO-2009082471-A1 STABLE LAQUINIMOD PREPARATIONS TEVA PHARMACEUTICAL INDUSTRIES, LTD. (IL) 2009-07-02 WO claimed
WO-2017019862-A1 COMBINATION FORMULATION OF LAQUINIMOD AND GLATIRAMER ACETATE WITH AMINO ACIDS TEVA PHARMACEUTICALS INDUSTRIES LTD. (IL) 2017-02-02 WO disclosed
EP-2597954-A1 DEUTERATED N-ETHYL-N-PHENYL-1,2-DIHYDRO-4-HYDROXY-5-CHLORO-1-METHYL-2-OXOQUINOLINE-3-CARBOXAMIDE, SALTS AND USES THEREOF Teva Pharmaceutical Industries Ltd. (IL) 2013-06-05 EP disclosed
EP-2590653-A1 5-CHLORO-4-HYDROXY-1-METHYL-2-OXO-N-PHENYL-1,2-DIHYDROQUINOLINE-3-CARBOXAMIDE, SALTS AND USES THEREOF Teva Pharmaceutical Industries Ltd. (IL) 2013-05-15 EP disclosed
WO-2012006538-A1 DEUTERATED N-ETHYL-N-PHENYL-1,2-DIHYDRO-4-HYDROXY-5-CHLORO-1-METHYL-2-OXOQUINOLINE-3-CARBOXAMIDE, SALTS AND USES THEREOF TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) 2012-01-12 WO disclosed
WO-2012006544-A1 5-CHLORO-4-HYDROXY-1-METHYL-2-OXO-N-PHENYL-1,2-DIHYDROQUINOLINE-3-CARBOXAMIDE, SALTS AND USES THEREOF TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) 2012-01-12 WO disclosed
EP-2376456-A2 HIGHLY PURE LAQUINIMOD OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF Actavis Group Ptc Ehf (IS) 2011-10-19 EP disclosed
EP-2318371-A2 NOVEL SOLID STATE FORMS OF LAQUINIMOD AND ITS SODIUM SALT Actavis Group PTC EHF (IS) 2011-05-11 EP disclosed
EP-2234485-A1 STABLE LAQUINIMOD PREPARATIONS Teva Pharmaceutical Industries Ltd. (IL) 2010-10-06 EP disclosed
WO-2010070449-A2 HIGHLY PURE LAQUINIMOD OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF ACTAVIS GROUP PTC EHF (IS) 2010-06-24 WO disclosed
WO-2010001257-A2 NOVEL SOLID STATE FORMS OF LAQUINIMOD AND ITS SODIUM SALT ACTAVIS GROUP PTC EHF (IS) 2010-01-07 WO disclosed
WO-2009082471-A1 STABLE LAQUINIMOD PREPARATIONS TEVA PHARMACEUTICAL INDUSTRIES, LTD. (IL) 2009-07-02 WO disclosed
EP-2035001-A2 STABLE LAQUINIMOD PREPARATIONS Teva Pharmaceutical Industries Limited (IL) 2009-03-18 EP disclosed
WO-2007146248-A2 STABLE LAQUINIMOD PREPARATIONS TEVA PHARMACEUTICAL INDUSTRIES, LTD. (IL) 2007-12-21 WO disclosed